Mohamad Hanouneh
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Mohamad Hanouneh has a total of 47 co-authors. Here are the top co-authors by number of shared publications:
Alice Chedid
A Department of Internal Medicine, Division of Nephrology , Johns Hopkins University Hospital , Baltimore , MD, USA
3 shared publicationsCarmen Elena Cervantes
Johns Hopkins Univ, Sch Med, Dept Med, Div Nephrol, Baltimore, MD USA
3 shared publications- Carmen Elena Cervantes
Division of Nephrology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland
3 shared publications - Bernard G. Jaar
Johns Hopkins University School of Medicine
2 shared publications C. Elena Cervantes
Johns Hopkins Univ, Dept Med, Div Nephrol, Baltimore, MD USA
2 shared publications- Christina Tamargo
Division of Nephrology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA
2 shared publications
Latest Publications
- 20 November 2024
- Published by Elsevier in Kidney International
- Vol. 106 (6) , 1190
Chylothorax and chylopericardium in a dialysis patient
- 20 November 2024
- Published by Elsevier in Kidney International
- Vol. 106 (6) , 1190
Chylothorax and chylopericardium in a dialysis patient
- Open Access
- 26 June 2024
- Published by MDPI AG in Diagnostics
- Vol. 14 (13) , 1357
Real-Life Experience on the Effect of SGLT2 Inhibitors vs. Finerenone vs. Combination on Albuminuria in Chronic Kidney Disease
Background: There have been several recent advances in the care of patients with chronic kidney disease (CKD), including the use of sodium glucose cotransporter 2 (SGLT2) inhibitors and selective mineralocorticoid receptor antagonists (MRAs). There are very few data reporting the outcomes of these treatments in real-world experience. The aim of this retrospective study is to report the effects of SGLT2 inhibitors, finerenone, and their combination in CKD patients in our community-based setting. Methods: Ninety-eight patients with CKD with an estimated glomerular filtration rate (eGFR) between 25 and 90 mL/min per 1.73 m2 and a urine albumin-to-creatinine ratio (UACR) ≥ 30 mg/g were included. Patients were divided into three groups: two monotherapy groups of SGLT2 inhibitors or finerenone and a third combination group of therapy with SGLT2 inhibitors for the first 4 months and SGLT2 inhibitors and finerenone subsequently. The primary outcomes were the timing and percentage of patients achieving a >50% reduction in UACR from baseline. Results: Group 1 comprised 52 patients on SGLT2i, group 2 had 22 patients on finerenone, and group 3 had 24 patients on combination therapy. The baseline median UACR and mean eGFR were 513 mg/g and 47.9 mL/min per 1.73 m2 in group 1, 548.0 mg/g and 50.5 mL/min per 1.73 m2 in group 2, and 800 mg/g and 60 mL/min per 1.73 m2 in group 3. At baseline, 71 (72.4%) patients were on the angiotensin-converting enzyme inhibitor (ACEi) or the angiotensin receptor blocker (ARB), and 78 (79.5%) patients had type 2 diabetes. After 8 months of follow-up, a >50% decrease in albuminuria was achieved in 96% of patients in group 3, compared to 50% in group 1 and 59% in group 2 (p-values were p-value: p-value: 2 in groups 1, 2, and 3, respectively, without a statistically significant difference between groups. Conclusions: In this real-world experience in our community setting, the combination of SGLT2 inhibitors and finerenone in our adult patients with CKD was associated with a very significant and clinically relevant reduction in UACR, without an increased risk of hyperkalemia. Combination therapy of SGLT2 inhibitor and finerenone regarding background use of ACEi/ARB is feasible and should be encouraged for further albuminuria reductions in CKD patients.
- 26 June 2024
- Published by MDPI AG in Diagnostics
- Vol. 14 (13) , 1357
Open AccessReal-Life Experience on the Effect of SGLT2 Inhibitors vs. Finerenone vs. Combination on Albuminuria in Chronic Kidney Disease
Background: There have been several recent advances in the care of patients with chronic kidney disease (CKD), including the use of sodium glucose cotransporter 2 (SGLT2) inhibitors and selective mineralocorticoid receptor antagonists (MRAs). There are very few data reporting the outcomes of these treatments in real-world experience. The aim of this retrospective study is to report the effects of SGLT2 inhibitors, finerenone, and their combination in CKD patients in our community-based setting. Methods: Ninety-eight patients with CKD with an estimated glomerular filtration rate (eGFR) between 25 and 90 mL/min per 1.73 m2 and a urine albumin-to-creatinine ratio (UACR) ≥ 30 mg/g were included. Patients were divided into three groups: two monotherapy groups of SGLT2 inhibitors or finerenone and a third combination group of therapy with SGLT2 inhibitors for the first 4 months and SGLT2 inhibitors and finerenone subsequently. The primary outcomes were the timing and percentage of patients achieving a >50% reduction in UACR from baseline. Results: Group 1 comprised 52 patients on SGLT2i, group 2 had 22 patients on finerenone, and group 3 had 24 patients on combination therapy. The baseline median UACR and mean eGFR were 513 mg/g and 47.9 mL/min per 1.73 m2 in group 1, 548.0 mg/g and 50.5 mL/min per 1.73 m2 in group 2, and 800 mg/g and 60 mL/min per 1.73 m2 in group 3. At baseline, 71 (72.4%) patients were on the angiotensin-converting enzyme inhibitor (ACEi) or the angiotensin receptor blocker (ARB), and 78 (79.5%) patients had type 2 diabetes. After 8 months of follow-up, a >50% decrease in albuminuria was achieved in 96% of patients in group 3, compared to 50% in group 1 and 59% in group 2 (p-values were p-value: p-value: 2 in groups 1, 2, and 3, respectively, without a statistically significant difference between groups. Conclusions: In this real-world experience in our community setting, the combination of SGLT2 inhibitors and finerenone in our adult patients with CKD was associated with a very significant and clinically relevant reduction in UACR, without an increased risk of hyperkalemia. Combination therapy of SGLT2 inhibitor and finerenone regarding background use of ACEi/ARB is feasible and should be encouraged for further albuminuria reductions in CKD patients.
- Open Access
- 3 June 2024
- Published by Cleveland Clinic Journal of Medicine in Cleveland Clinic Journal of Medicine
- Vol. 91 (6) , 345-351
A hidden cause of hypokalemia
- 3 June 2024
- Published by Cleveland Clinic Journal of Medicine in Cleveland Clinic Journal of Medicine
- Vol. 91 (6) , 345-351
Open AccessA hidden cause of hypokalemia
- Top Cited PapersOpen Access
- 23 April 2024
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (9) , 2455
Treatment of Acute Kidney Injury: A Review of Current Approaches and Emerging Innovations
Acute kidney injury (AKI) is a complex and life-threatening condition with multifactorial etiologies, ranging from ischemic injury to nephrotoxic exposures. Management is founded on treating the underlying cause of AKI, but supportive care—via fluid management, vasopressor therapy, kidney replacement therapy (KRT), and more—is also crucial. Blood pressure targets are often higher in AKI, and these can be achieved with fluids and vasopressors, some of which may be more kidney-protective than others. Initiation of KRT is controversial, and studies have not consistently demonstrated any benefit to early start dialysis. There are no targeted pharmacotherapies for AKI itself, but some do exist for complications of AKI; additionally, medications become a key aspect of AKI management because changes in renal function and dialysis support can lead to issues with both toxicities and underdosing. This review will cover existing literature on these and other aspects of AKI treatment. Additionally, this review aims to identify gaps and challenges and to offer recommendations for future research and clinical practice.
- 23 April 2024
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (9) , 2455
Top Cited PapersOpen AccessTreatment of Acute Kidney Injury: A Review of Current Approaches and Emerging Innovations
Acute kidney injury (AKI) is a complex and life-threatening condition with multifactorial etiologies, ranging from ischemic injury to nephrotoxic exposures. Management is founded on treating the underlying cause of AKI, but supportive care—via fluid management, vasopressor therapy, kidney replacement therapy (KRT), and more—is also crucial. Blood pressure targets are often higher in AKI, and these can be achieved with fluids and vasopressors, some of which may be more kidney-protective than others. Initiation of KRT is controversial, and studies have not consistently demonstrated any benefit to early start dialysis. There are no targeted pharmacotherapies for AKI itself, but some do exist for complications of AKI; additionally, medications become a key aspect of AKI management because changes in renal function and dialysis support can lead to issues with both toxicities and underdosing. This review will cover existing literature on these and other aspects of AKI treatment. Additionally, this review aims to identify gaps and challenges and to offer recommendations for future research and clinical practice.
- Open Access
- 1 March 2024
- Published by Cleveland Clinic Journal of Medicine in Cleveland Clinic Journal of Medicine
- Vol. 91 (3) , 155-160
Multiple metabolic renal manifestations of a systemic disease
Multiple metabolic renal manifestations of a systemic disease A 39-year-old woman with a history of depression,
- 1 March 2024
- Published by Cleveland Clinic Journal of Medicine in Cleveland Clinic Journal of Medicine
- Vol. 91 (3) , 155-160
Open AccessMultiple metabolic renal manifestations of a systemic disease
Multiple metabolic renal manifestations of a systemic disease A 39-year-old woman with a history of depression,
- 21 September 2023
- Published by Elsevier in The Lancet
- Vol. 402 (10407) , 1083-1084
Ichthyosis in sarcoidosis: a rare skin manifestation of a systemic disease
- 21 September 2023
- Published by Elsevier in The Lancet
- Vol. 402 (10407) , 1083-1084
Ichthyosis in sarcoidosis: a rare skin manifestation of a systemic disease
- 20 September 2023
- Published by Elsevier in American Journal of Kidney Diseases
- Vol. 82 (4) , A11-A14
A Young Man With Chronic Refractory Hypokalemia: A Quiz
- 20 September 2023
- Published by Elsevier in American Journal of Kidney Diseases
- Vol. 82 (4) , A11-A14
A Young Man With Chronic Refractory Hypokalemia: A Quiz
- Open Access
- 1 June 2023
- Published by Wolters Kluwer Health in Kidney360
- Vol. 4 (6) , e863-e864
Rash and Nephrotic Syndrome in a Patient with Rheumatoid Arthritis
Export
- 1 June 2023
- Published by Wolters Kluwer Health in Kidney360
- Vol. 4 (6) , e863-e864
Open AccessRash and Nephrotic Syndrome in a Patient with Rheumatoid Arthritis
Export
- Open Access
- 7 October 2022
- Published by Springer Nature in BMC Medicine
- Vol. 20 (1) , 1-5
From screening to treatment: the new landscape of diabetic kidney disease
Globally, diabetes mellitus is the leading cause of chronic kidney disease (CKD), and it is predicted to increase in the following years. Despite its high prevalence, CKD remains under diagnosed. In this BMC Medicine collection of articles on diabetic kidney disease (DKD), we place in context the importance of screening and early detection of DKD and the most accurate tools to monitor for optimal glycemic control in this his risk population. Further, we address this population's risk for severe complications such as stroke and all-cause mortality. We close this editorial by summarizing recent advances in management of this vulnerable population of patients with DKD, including guideline-directed medical therapy, novel treatments, and predictors of treatment failure.
- 7 October 2022
- Published by Springer Nature in BMC Medicine
- Vol. 20 (1) , 1-5
Open AccessFrom screening to treatment: the new landscape of diabetic kidney disease
Globally, diabetes mellitus is the leading cause of chronic kidney disease (CKD), and it is predicted to increase in the following years. Despite its high prevalence, CKD remains under diagnosed. In this BMC Medicine collection of articles on diabetic kidney disease (DKD), we place in context the importance of screening and early detection of DKD and the most accurate tools to monitor for optimal glycemic control in this his risk population. Further, we address this population's risk for severe complications such as stroke and all-cause mortality. We close this editorial by summarizing recent advances in management of this vulnerable population of patients with DKD, including guideline-directed medical therapy, novel treatments, and predictors of treatment failure.
- 25 November 2020
- Published by Wolters Kluwer Health in Kidney360
- Vol. 1 (11) , 1330-1331
Apparent AKI in a Patient with Ascites Following Laparoscopic Hysterectomy
- 25 November 2020
- Published by Wolters Kluwer Health in Kidney360
- Vol. 1 (11) , 1330-1331
Apparent AKI in a Patient with Ascites Following Laparoscopic Hysterectomy